The recommended phase II dose was determined to be 300 mg once daily and the FDA approved avapritinib in January 2020 for adults with inoperable GIST harboring a PDGFRA exon 18 mutations, including the D842V mutation. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.